BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18538173)

  • 1. Introduction. The novel microtubule inhibitor vinflunine.
    Horwitz SB
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S1-2. PubMed ID: 18538173
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics, metabolites, and preclinical safety of vinflunine.
    Lobert S; Puozzo C
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S28-33. PubMed ID: 18538176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential mechanisms of resistance to microtubule inhibitors.
    Kavallaris M; Annereau JP; Barret JM
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
    Jordan MA; Horwitz SB; Lobert S; Correia JJ
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules.
    Ngan VK; Bellman K; Panda D; Hill BT; Jordan MA; Wilson L
    Cancer Res; 2000 Sep; 60(18):5045-51. PubMed ID: 11016627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of vinflunine: effector pathways and potential for synergies.
    Braguer D; Barret JM; McDaid H; Kruczynski A
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S13-21. PubMed ID: 18538174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
    Bellmunt J; Delgado FM; George C
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S34-43. PubMed ID: 18538178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinflunine: discovery and synthesis of a novel microtubule inhibitor.
    Fahy J; Hellier P; Breillout F; Bailly C
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S3-5. PubMed ID: 18538177
    [No Abstract]   [Full Text] [Related]  

  • 9. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells.
    Jean-Decoster C; Brichese L; Barret JM; Tollon Y; Kruczynski A; Hill BT; Wright M
    Anticancer Drugs; 1999 Jul; 10(6):537-43. PubMed ID: 10885901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.
    Makarov AA; Tsvetkov PO; Villard C; Esquieu D; Pourroy B; Fahy J; Braguer D; Peyrot V; Lafitte D
    Biochemistry; 2007 Dec; 46(51):14899-906. PubMed ID: 18052208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.
    Kruczynski A; Hill BT
    Crit Rev Oncol Hematol; 2001 Nov; 40(2):159-73. PubMed ID: 11682323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of C-12' substituted vinflunine derivatives.
    Lei XS; Yu XD; Yin L; Liu ZH; Tang PC
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4602-5. PubMed ID: 18653334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity.
    Aparicio LM; Pulido EG; Gallego GA
    Anticancer Drugs; 2012 Jan; 23(1):1-11. PubMed ID: 22027536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity.
    Lobert S; Ingram JW; Hill BT; Correia JJ
    Mol Pharmacol; 1998 May; 53(5):908-15. PubMed ID: 9584218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinflunine, a second generation novel Vinca Alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers.
    Hill BT
    Curr Pharm Des; 2001 Sep; 7(13):1199-212. PubMed ID: 11472262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine.
    Estève MA; Carré M; Bourgarel-Rey V; Kruczynski A; Raspaglio G; Ferlini C; Braguer D
    Mol Cancer Ther; 2006 Nov; 5(11):2824-33. PubMed ID: 17121929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biological characteristics of microtubule and related drug research].
    Li JN; Jiang JD
    Yao Xue Xue Bao; 2003 Apr; 38(4):311-5. PubMed ID: 12889136
    [No Abstract]   [Full Text] [Related]  

  • 18. Vinflunine: a new microtubule inhibitor agent.
    Bennouna J; Delord JP; Campone M; Nguyen L
    Clin Cancer Res; 2008 Mar; 14(6):1625-32. PubMed ID: 18347163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vinflunine: a fluorinated vinca alkaloid for bladder cancer therapy.
    Gerullis H
    Drugs Today (Barc); 2011 Jan; 47(1):17-25. PubMed ID: 21373647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vinflunine: clinical perspectives of an emerging anticancer agent.
    Yun-San Yip A; Yuen-Yuen Ong E; Chow LW
    Expert Opin Investig Drugs; 2008 Apr; 17(4):583-91. PubMed ID: 18363522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.